Cipla is currently trading at Rs. 562.50, up by 5.20 points or 0.93% from its previous closing of Rs. 557.30 on the BSE.
The scrip opened at Rs. 561.75 and has touched a high and low of Rs. 565.40 and Rs. 559.00 respectively. So far 32490 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 575.20 on 02-Sep-2014 and a 52 week low of Rs. 366.70 on 24-Feb-2014.
Last one week high and low of the scrip stood at Rs. 575.20 and Rs. 515.00 respectively. The current market cap of the company is Rs. 44746.81 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 35.85% and 26.23% respectively.
Cipla’s wholly owned subsidiary - Medispray Laboratories, has received an approval for acquisition of two manufacturing undertakings. A significant portion of the capacities of the two undertakings are dedicated for the manufacture of Cipla’s products. The acquisition of the aforesaid undertakings is expected to yield operational synergies. The board of directors at their meeting held on September 05, 2014 has approved for the same.
The consideration for the above two transactions are Rs 29 crore and Rs 71.93 crore respectively. The first manufacturing facility located at Goa is owned by Okasa and the second manufacturing facility located at Satara (Maharashtra) is owned by Okasa Pharma, the entities controlled by relatives of the promoters hold majority interest in the companies which own the aforesaid undertakings.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: